首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

2126427

集中式測試服務市場－策略分析與預測（2026-2035）

Central Laboratory Services Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月11日 | 出版商:

Knowledge Sourcing Intelligence | 英文 178 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

集中式測試服務市場預計將以 10.4% 的複合年成長率成長，從 2026 年的 117.8 億美元成長到 2035 年的 286.7 億美元。

全球集中式化驗服務服務市場正經歷強勁成長，這主要得益於臨床研究日益複雜化以及精準醫療的蓬勃發展。集中式實驗室服務已成為臨床研究的重要組成部分，能夠為地理位置分散的臨床試驗中心提供標準化的分析檢測。隨著製藥公司需要可靠的檢測數據來支援日益複雜的生物標記主導療法、基因組醫學和個人化治療方案，市場需求不斷成長。國際臨床試驗中多樣化的監管要求增加了營運的複雜性，要求實驗室維護全球統一的品質系統和檢驗的分析流程。集中式實驗室服務提供者正在整合自動化、人工智慧、數位病理學和實驗室資訊管理系統，以提高營運效率，並在整個臨床開發過程中保持資料的完整性。該市場佔據著重要的戰略地位，因為檢測性能的一致性直接影響監管申報、患者安全評估、終點評估以及創新療法的商業化。

市場促進因素

擴大精準醫療臨床試驗

在精準醫療領域，患者選擇越來越依賴基因生物標記和伴隨診斷，這要求檢測高度標準化。隨著製藥公司開發標靶治療，需要在多個臨床試驗中心實現一致的分析效能，市場需求正轉向集中式檢測服務。獨立檢測結果可能有差異，進而影響生物標記的解讀和法規核准。集中式檢測服務提供者正在擴展其先進的分子診斷、基因測序和整合生物資訊能力，以提高整個臨床開發過程中資料的可重複性。這種轉變將增強對臨床終點的信心，並有助於更有效率地完成監管申報。

製藥和生技公司外包業務增加

隨著臨床研究項目日益全球化和營運複雜化，製藥研發公司正在擴大檢測外包業務。市場對能夠整合檢體物流、專業檢測、法規專業知識和數位資料管理等服務的綜合性檢測合作夥伴的需求日益成長。維護內部偵測基礎設施需要大量投資，同時也會限制跨國研究的營運柔軟性。集中式檢測服務供應商正在擴展其全球檢測網路和標準化流程，從而提高擴充性並減輕臨床試驗申辦方的工作量。外包仍然是一種策略性方法，使研究機構能夠集中資源用於創新療法的研發。

基於生物標記的藥物發現方法已被廣泛應用

生物標記在現代臨床研究中發揮著至關重要的作用，能夠改善患者分層、治療監測和治療反應評估。隨著以生物標記主導的臨床試驗設計在腫瘤學、免疫學和罕見疾病領域的研發中日益受到重視，專業檢測服務的需求也隨之成長。傳統實驗室往往缺乏進行高階分子分析所需的專業知識。中心檢查室正投資於高通量定序、多重檢測和經驗證的生物標記平台，以提高分析準確性並支持個人化醫療。這些能力能夠提高臨床試驗的效率，並增強治療檢驗的信心。

全球臨床試驗日益複雜

隨著申辦者對患者群體多樣性和受試者招募速度的要求日益提高，臨床試驗擴大跨越多個國家。全球性研究需要統一的分析方法、標準化的品質系統和一致的監管文件，促使研究模式轉向集中式檢查室模式。各地檢查室操作的差異為數據可比性和終點有效性帶來了挑戰。集中式檢查室機構正在加強國際物流網路、數位化檢查室資訊系統和統一的品管系統，以提高跨國研究計畫的營運一致性。在日益複雜的臨床開發環境中，標準化是產生可靠數據的基礎。

市場限制因素

與全球檢體物流、冷鏈運輸和專業檢查室基礎設施相關的高昂營運成本持續限制服務供應商的盈利。多樣化的國際監管要求和各國特定的進出口法規使跨國臨床試驗的運作變得複雜。高技能分子科學家、檢查室專家和生物資訊學專家的短缺持續限制先進檢測服務的擴展。

市場定義和範圍
行業概覽
產業變化
主要市場趨勢
過往市場分析
市場預測
集中式檢查室的工作流程分析
臨床試驗網路分析
與檢體物流和生物檢體資料庫管理相關的分析範例
數位檢查室資訊學和數據整合的發展趨勢
生物標記伴隨診斷服務分析

第4章市場動態

市場促進因素
市場限制因素
市場機遇
市場挑戰

第5章行業情勢

產業價值鏈分析
定價分析
集中式測試服務的生態系分析
臨床試驗外包的現狀

第6章：創新趨勢

新興技術
人工智慧在臨床試驗實驗室的應用
實驗室自動化和機器人技術
數位病理學和生物標記創新
分散式臨床試驗（DCT）的整合
基於雲端的實驗室資訊管理系統（LIMS）

第7章監理情勢

法律規範
臨床實驗室檢測正確實施標準（GCLP）
檢查室認證和品管合規性

第8章集中式測驗服務市場：展望分析

分析：依服務類型
分析：按治療領域
分析：按最終用戶

第9章集中式測試服務市場：細分市場分析

按服務類型
- 生物標記檢測服務
- 基因和基因組檢測服務
- 臨床化學檢測
- 微生物檢測
- 組織病理學和細胞病理學服務
- 檢體管理和生物檢體資料庫服務
- 藥物動力學 (PK) 與動態(PD) 研究
- 安全測試服務
按治療區域
- 腫瘤學
- 心血管疾病
- 感染疾病
- 神經病學
- 免疫學與自體免疫疾病
- 代謝性疾病
- 罕見疾病
最終用戶
- 製藥公司
- 生技公司
- 受託研究機構（CRO）
- 學術研究機構
- 醫療設備製造商

第10章集中式偵測服務市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章集中式測驗服務市場：國家分析

美國
加拿大
德國
英國
法國
義大利
西班牙
荷蘭
瑞士
中國
日本
印度
韓國
澳洲
巴西
沙烏地阿拉伯
南非

第12章競爭格局

市佔率分析
策略趨勢
併購、合作與聯盟
服務拓展與技術創新

第13章：公司簡介

Labcorp Drug Development
ICON plc
IQVIA Inc.
Thermo Fisher Scientific Inc.
Medpace Holdings, Inc.
Eurofins Scientific SE
Charles River Laboratories International, Inc.
Q2 Solutions（IQVIA）
Cerba Research
ACM Global Laboratories
Frontage Laboratories, Inc.
WuXi AppTec Co., Ltd.
LabConnect LLC
SGS SA
NAMSA

第14章集中式測驗服務市場：商業預測分析

第15章：投資與資金籌措分析

對臨床研究基礎設施的投資
政府資助臨床研究和測試網路
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009145

The Central Laboratory Services Market is forecast to grow at a CAGR of 10.4%, reaching USD 28.67 billion in 2035 from USD 11.78 billion in 2026.

The global central laboratory services market is experiencing robust growth, driven by the increasing complexity of clinical research and the expansion of precision medicine. Central laboratory services form an essential component of clinical research by delivering standardized analytical testing across geographically dispersed clinical trial sites. Demand is increasing as drug developers require reliable laboratory data that support increasingly sophisticated biomarker-driven therapies, genomic medicine, and personalized treatment approaches. Diverse regulatory requirements across international clinical trials create operational complexity that requires laboratories to maintain globally harmonized quality systems and validated analytical processes. Central laboratory providers are integrating automation, artificial intelligence, digital pathology, and laboratory information management systems to strengthen operational efficiency while maintaining data integrity throughout clinical development. The market holds strategic importance because consistent laboratory performance directly influences regulatory submissions, patient safety assessments, endpoint evaluation, and the successful commercialization of innovative therapeutics.

Market Drivers

Expansion of Precision Medicine Clinical Trials

Precision medicine requires highly standardized laboratory testing because patient selection increasingly depends on genomic biomarkers and companion diagnostics. Demand is shifting toward centralized laboratory services as pharmaceutical companies develop targeted therapies that require consistent analytical performance across multiple clinical trial locations. Independent laboratory testing introduces variability that may affect biomarker interpretation and regulatory acceptance. Central laboratories are expanding advanced molecular diagnostics, genomic sequencing, and integrated bioinformatics capabilities that improve data reproducibility throughout clinical development. This transition strengthens confidence in clinical endpoints while supporting more efficient regulatory submissions.

Increasing Outsourcing by Pharmaceutical and Biotechnology Companies

Drug developers increasingly outsource laboratory operations because clinical research programs are becoming more global and operationally complex. Demand is growing for comprehensive laboratory partners that combine specimen logistics, specialized testing, regulatory expertise, and digital data management within a unified service model. Maintaining internal laboratory infrastructure requires significant investment while limiting operational flexibility across multinational studies. Central laboratory providers are expanding global laboratory networks and standardized operating procedures that improve scalability and reduce operational burden for clinical sponsors. Outsourcing remains a strategic approach that enables research organizations to focus resources on therapeutic innovation.

Growing Adoption of Biomarker-Based Drug Development

Biomarkers play a critical role in modern clinical research because they improve patient stratification, treatment monitoring, and therapeutic response evaluation. Demand is increasing for specialized laboratory services as oncology, immunology, and rare disease pipelines continue emphasizing biomarker-driven clinical trial designs. Conventional laboratory capabilities often lack the specialized technologies required for advanced molecular analysis. Central laboratories are investing in high-throughput sequencing, multiplex assays, and validated biomarker platforms that improve analytical precision and support personalized medicine. These capabilities strengthen clinical trial efficiency and increase confidence in therapeutic decision-making.

Rising Complexity of Global Clinical Trials

Clinical trials increasingly span multiple countries because sponsors seek diverse patient populations and accelerated recruitment. Demand is shifting toward centralized laboratory models as global studies require harmonized analytical methods, standardized quality systems, and consistent regulatory documentation. Variability in local laboratory practices creates challenges for data comparability and endpoint validation. Central laboratory organizations are strengthening international logistics networks, digital laboratory informatics, and unified quality management systems that improve operational consistency throughout multinational research programs. Standardization supports reliable data generation across increasingly complex clinical development environments.

Market Restraints

High operational costs associated with global specimen logistics, cold-chain transportation, and specialized laboratory infrastructure continue limiting profitability for service providers. Diverse international regulatory requirements and country-specific import-export restrictions create operational complexity for multinational clinical trials. Shortages of highly skilled molecular scientists, laboratory specialists, and bioinformatics professionals continue constraining expansion of advanced laboratory services.

Technology and Segment Insights

By Service Type

Biomarker testing services represent one of the fastest-evolving segments because modern drug development increasingly depends on biological markers that improve patient selection, treatment monitoring, and therapeutic response assessment. Demand is shifting toward centralized biomarker laboratories as pharmaceutical companies expand precision medicine programs across oncology, immunology, and rare disease clinical trials. Genetic and genomic testing services are critical for patient stratification and companion diagnostic development. Clinical chemistry, microbiology, histopathology, and cytopathology services support safety and efficacy evaluation. Specimen management and biorepository services are essential for long-term sample storage. Pharmacokinetic (PK) and pharmacodynamic (PD) testing supports drug concentration and effect analysis. Safety testing services are fundamental for patient monitoring.

By Therapeutic Area

Oncology represents the largest therapeutic application because cancer drug development increasingly relies on biomarker-guided patient selection, genomic profiling, and companion diagnostics. Demand is shifting toward centralized laboratory services as immunotherapies and targeted therapies require standardized molecular testing. Cardiovascular diseases, infectious diseases, neurology, immunology and autoimmune diseases, metabolic disorders, and rare diseases represent significant and growing segments. Standardized laboratory support enables more precise patient stratification and strengthens evidence generation for innovative therapies across these areas.

By End User

Pharmaceutical companies represent the largest end-user segment because global drug development programs require standardized laboratory testing throughout every phase of clinical research. Demand is increasing as pipelines become increasingly focused on precision medicine and complex therapeutic modalities. Biotechnology companies are significant users, particularly for specialized biomarker and genomic testing. Contract Research Organizations (CROs) utilize central laboratory services to support outsourced clinical trials. Academic and research institutes and medical device companies also contribute to market demand.

Competitive and Strategic Outlook

The competitive landscape features major CROs and specialized laboratory service providers. Labcorp Drug Development combines one of the world's largest central laboratory networks with comprehensive drug development services. ICON plc differentiates itself through its fully integrated clinical research platform combining central laboratory services with clinical trial management. IQVIA Inc. integrates central laboratory capabilities with clinical technology, healthcare analytics, and real-world evidence platforms. Thermo Fisher Scientific Inc. offers a broad portfolio of laboratory technologies, specialty diagnostics, and clinical research services. Medpace Holdings, Inc. is distinguished by its therapeutic specialization and integrated clinical research model. Eurofins Scientific SE operates one of the broadest international laboratory networks. Charles River Laboratories combines preclinical research expertise with specialized laboratory services. Q2 Solutions (IQVIA) focuses exclusively on central laboratory services, biomarker testing, and translational medicine.
Strategic developments include increasing integration of artificial intelligence and digital pathology, expansion of decentralized clinical trial support, and growth of companion diagnostic services. Companies are forming partnerships to enhance global logistics, analytical capabilities, and regulatory expertise. Service expansions focus on advanced molecular testing, genomic sequencing, and integrated data management. Companies that successfully combine scientific specialization, digital innovation, global infrastructure, and regulatory expertise are expected to strengthen their competitive positions.

Conclusion

The central laboratory services market is poised for substantial growth, driven by the expansion of precision medicine, increasing outsourcing, and the rising complexity of global clinical trials. The evolution toward integrated, technology-enabled laboratory networks supporting complex drug development is reshaping the market. Companies that successfully deliver standardized, high-quality, and digitally connected laboratory services are expected to lead the market. Ongoing technological innovation, regulatory support, and expanding clinical research infrastructure across emerging economies will further accelerate adoption throughout the forecast period.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Central Laboratory Services Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Industry Overview
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Historical Market Analysis (2021-2025)
3.6 Market Forecast (2026-2035)
3.7 Central Laboratory Workflow Analysis
3.8 Clinical Trial Laboratory Network Analysis
3.9 Sample Logistics & Biorepository Management Analysis
3.10 Digital Laboratory Informatics & Data Integration Trends
3.11 Biomarker & Companion Diagnostic Service Analysis

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Central Laboratory Service Ecosystem Analysis
5.4 Clinical Trial Outsourcing Landscape

6. Innovation Landscape

6.1 Emerging Technologies
6.2 Artificial Intelligence in Clinical Trial Laboratories
6.3 Laboratory Automation & Robotics
6.4 Digital Pathology & Biomarker Innovation
6.5 Decentralized Clinical Trial (DCT) Integration
6.6 Cloud-Based Laboratory Information Management Systems (LIMS)

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Good Clinical Laboratory Practice (GCLP) Standards
7.3 Laboratory Accreditation & Quality Compliance

8. Central Laboratory Services Market Landscape Analysis

8.1 Analysis by Service Type
8.2 Analysis by Therapeutic Area
8.3 Analysis by End User

9. Central Laboratory Services Market Segment Analysis (2021-2035)

9.1 By Service Type
- 9.1.1 Biomarker Testing Services
- 9.1.2 Genetic & Genomic Testing Services
- 9.1.3 Clinical Chemistry Testing
- 9.1.4 Microbiology Testing
- 9.1.5 Histopathology & Cytopathology Services
- 9.1.6 Specimen Management & Biorepository Services
- 9.1.7 Pharmacokinetic (PK) & Pharmacodynamic (PD) Testing
- 9.1.8 Safety Testing Services
9.2 By Therapeutic Area
- 9.2.1 Oncology
- 9.2.2 Cardiovascular Diseases
- 9.2.3 Infectious Diseases
- 9.2.4 Neurology
- 9.2.5 Immunology & Autoimmune Diseases
- 9.2.6 Metabolic Disorders
- 9.2.7 Rare Diseases
9.3 By End User
- 9.3.1 Pharmaceutical Companies
- 9.3.2 Biotechnology Companies
- 9.3.3 Contract Research Organizations (CROs)
- 9.3.4 Academic & Research Institutes
- 9.3.5 Medical Device Companies